MOG and myeloid sarcoma: There is a discrepancy between the lack of MOG-IgG in the MS control group in this study and the fact that MS had been suspected by the then treating physicians at least once in 16/45 (35.6 %) MOG-IgG positive patients, as outlined in part 2 of this series [36].